Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol VRTX
Vertex Pharmaceuticals
VRTX
85
$480.73arrow_drop_up0.35%$1.70
High Quality
S&P500

Performance History

Chart placeholder
Key Stats
Open$477.73
Prev. Close$479.03
EPS15.43
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$113.54B
PE Ratio31.16
LOWHIGH
Day Range477.73
483.53
52 Week Range335.82
486.42
Ratios
P/B Ratio5.83
Revenue$9.83B
Operating M. %45.20%
Earnings$3.61B
Earnings Growth %8.96%
EBITDA Margin %46.59%
ROE %24.38%
EPS15.43

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Reshma Kewalramani FASN, M.D.
Headquarters
Boston
Employees
4800
Exchange
NASDAQ
add Vertex Pharmaceuticals  to watchlist

Keep an eye on Vertex Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Vertex Pharmaceuticals 's (VRTX) price per share?

The current price per share for Vertex Pharmaceuticals (VRTX) is $480.73. The stock has seen a price change of $1.7 recently, indicating a 0.35% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Vertex Pharmaceuticals (VRTX)?

For Vertex Pharmaceuticals (VRTX), the 52-week high is $486.43, which is 1.19% from the current price. The 52-week low is $335.82, the current price is 43.15% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Vertex Pharmaceuticals (VRTX) a growth stock?

Vertex Pharmaceuticals (VRTX) has shown an average price growth of 0.41% over the past three years. It has received a score of 83 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Vertex Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Vertex Pharmaceuticals (VRTX) stock price performance year to date (YTD)?

As of the latest data, Vertex Pharmaceuticals (VRTX) has a year-to-date price change of 16.99%. Over the past month, the stock has experienced a price change of 9.88%. Over the last three months, the change has been 17.92%. Over the past six months, the figure is 17.06%. Looking at a longer horizon, the five-year price change stands at 176.63%.

help
Is Vertex Pharmaceuticals (VRTX) a profitable company?

Vertex Pharmaceuticals (VRTX) has a net income of $3.62B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 87.17% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 45.2% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $9.84B, with a revenue growth rate of 10.17%, providing insight into the company's sales performance and growth. The gross profit is $8.58B. Operating income is noted at $3.75B. Furthermore, the EBITDA is $5.21B.

help
What is the market capitalization of Vertex Pharmaceuticals (VRTX)?

Vertex Pharmaceuticals (VRTX) has a market capitalization of $113.55B. The average daily trading volume is 1.13M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level